What I have: injection-site erythema · 1,200 kcal.
Before I write this off, I want to check whether it is a known failure mode.
I have the lot number, the certificate and the date, and I am happy to compare them against anything.
What is the differential here, and which test discriminates between the options?
Look at the placebo arm before concluding anything about attribution. The placebo-arm rates for most of these events are not small, because the events themselves are common in the underlying population.
Nausea incidence in the pivotal trials runs to roughly 40 to 45 per cent at the higher doses against 15 to 20 per cent on placebo, with vomiting at roughly 15 to 25 per cent against 5 to 8 per cent. Discontinuation specifically attributable to gastrointestinal adverse events was in the range of 4 to 7 per cent. Those are the numbers to hold in mind when someone describes their experience as unusual.
Pancreatitis red flags worth memorising rather than looking up: severe, persistent epigastric pain radiating to the back, worse lying flat and better sitting forward, with nausea and vomiting that does not settle. That combination is an urgent assessment, not a dose adjustment. An isolated lipase elevation without that picture is common and usually not pancreatitis.
The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.
The caveat that actually matters: this is pattern recognition from published data, not a clinical assessment of you. Anything severe, persistent or accompanied by systemic features belongs with a clinician the same day.
Write down in advance which symptoms mean stop and seek care. It is a short list and it is much easier to write when you are well.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsTiming is the most useful diagnostic feature here and it is the one most often omitted from the question.
Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.
Worth being precise here: the gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.
SURMOUNT-1 reported gastrointestinal events as the most frequent adverse events, mostly mild to moderate and mostly during escalation, with discontinuation for adverse events in the single digits per cent[1].
Worth being explicit: nothing here is medical advice, and research-use-only compounds are not approved for human use.
A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.
edited 14 Jun 2024 by s_kalniete — tightened the wording; no substantive change
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.